Arthneeti
NF

NGL Fine Chem

Q4 FY26Pharmaceuticals & Biotechnology

NGL Fine Chem Q4 FY26 Results & Concall Highlights: Capex ₹210 Cr

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹2,948
Market cap₹2.1K Cr
P/E42.3
Updated23 Aug 2026
Read5 min read

What the Q4 FY26 call signalled

2 of 4 strong

RevenueGood growth
MarginMargins steady
CapexCapex planned
FundraiseNo fundraise planned

The short version

Revenue growth has shown strong momentum with a 36% increase in FY26, driven by broad-based volume growth across products and geographies. - Volume growth is stable with demand recovery confirmed over the last three quarters, providing confidence for maintaining or improving current run rates. - New plant expansions are expected to add up to Rs. FY26 showed strong recovery with 36% revenue growth, 114% EBITDA increase, and 128% PAT growth. - Volume-led growth and capacity expansions are key growth drivers. - New plant Phase I is operational; Phase II commissioning expected early Q2 FY27, commercial production H2 FY27. - Partial price pass-through achieved; further margin improvement expected as commodity cost pressures stabilize. - EBITDA margin guidance remains 15%-18%; new regulated market segments could add 3%-5% margin premium. - Regulated market sales to start contributing meaningfully from FY28 onwards. - Peak revenue potential from new expansion estimated at Rs.

From NGL Fine Chem's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Good growth
  • Revenue growth has shown strong momentum with a 36% increase in FY26, driven by broad-based volume growth across products and geographies.
  • Volume growth is stable with demand recovery confirmed over the last three quarters, providing confidence for maintaining or improving current run rates.
  • New plant expansions are expected to add up to Rs. 350 crores in turnover over the next 3-4 years.
  • Regulated market sales (Europe starting FY27, US from FY28) will contribute meaningfully from FY28 onwards, though peak contributions are still to be crystallized.
  • The company aims to stabilize at a quarterly run rate of approx. Rs. 150 crore, with potential to exceed it over time.
  • Continued addition of 9-10 new products annually supports diversified growth.

2 more points management made on revenue & sales performance

Profitability & Margins

See what NGL Fine Chem said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Total planned CAPEX for the ongoing expansion program is ₹210 crores, with ₹182.75 crores invested up to Q4 FY26.
  • Phase II Greenfield expansion at Tarapur faced delays due to gas and labor shortages; commissioning rescheduled from Q1 FY27 to early Q2 FY27.
  • Commercial production for Phase II is expected to start from H2 FY27, as previously guided.
  • Post project completion, annual CAPEX is expected to be around ₹15-20 crores.
  • No additional large-scale CAPEX currently planned beyond this expansion.
  • Management is financing the cost increase internally, without additional borrowing.

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what NGL Fine Chem said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided in the document does not explicitly mention the current or expected order book or pending orders for NGL Fine-Chem Limited. However, the following relevant points related to future growth and demand can be noted: - Expect revenue run rate to stabilize around Rs. 150 crore quarterly, with new capacity utilization increasing over next 1-2 quarters. - Growth and demand stable for past three quarters, indicating strong order flow continuity. - Expansion plans anticipate generating Rs. 350 crore turnover from the new plant over the next 3-4 years. - Regulated market sales expected to start contributing significantly from FY’28 onwards.

2 more points management made on order book & pipeline

NGL Fine Chem — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹145 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What NGL Fine Chem Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Anuh Pharma Ltd (Q4 FY26)

    202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key investor presentation takeaways from Anuh Pharma Ltd's Q4 FY26 investor presentation — and how i

  • Themis Medicare Ltd (Q4 FY26)

    Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q4 FY26 inv

  • Remus Pharmaceuticals Ltd (Q4 FY26)

    Quarterly Revenue (H2-FY26):** INR 4,534 Mn, up 30.4% YoY from INR 3,478 Mn in H2-FY25 . Key investor presentation takeaways from Remus Pharmaceuticals Ltd's Q4

  • Lincoln Pharmaceuticals Ltd (Q4 FY26)

    EBITDA: ₹26 crore, a 3% year-on-year increase . Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how i

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were NGL Fine Chem Q4 FY26 results?

Revenue growth has shown strong momentum with a 36% increase in FY26, driven by broad-based volume growth across products and geographies. - Volume growth is stable with demand recovery confirmed over the last three quarters, providing confidence for maintaining or improving current run rates. - New plant expansions are expected to add up to Rs. FY26 showed strong recovery with 36% revenue growth, 114% EBITDA increase, and 128% PAT growth. - Volume-led growth and capacity expansions are key growth drivers. - New plant Phase I is operational; Phase II commissioning expected early Q2 FY27, commercial production H2 FY27. - Partial price pass-through achieved; further margin improvement expected as commodity cost pressures stabilize. - EBITDA margin guidance remains 15%-18%; new regulated market segments could add 3%-5% margin premium. - Regulated market sales to start contributing meaningfully from FY28 onwards. - Peak revenue potential from new expansion estimated at Rs.

What is NGL Fine Chem share price analysis?

NGL Fine Chem currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 42.3 with a market cap of ₹2,135 Cr. Investors should review the full earnings analysis for detailed insights.

Is NGL Fine Chem planning capital expenditure?

Total planned CAPEX for the ongoing expansion program is ₹210 crores, with ₹182.75 crores invested up to Q4 FY26.

Keep NGL Fine Chem on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.